RFA-Announcement of a Limited Competition for the Continuation of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial (U01)

The summary for the RFA-Announcement of a Limited Competition for the Continuation of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

RFA-Announcement of a Limited Competition for the Continuation of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial (U01): This is an announcement for a Limited Competition to solicit a single grant application from the Principal Investigator whose institution is currently serving as the Operations Center for the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. This Limited Competition will provide support for five years to Clinical Centers to continue recruitment, treatment, and follow-up of study participants enrolled in the trial. Support will also be provided for the Data Coordinating Center, the Central Laboratory, the Endpoint Adjudication Center, and the Operations Center.

Federal Grant Title:	RFA-Announcement of a Limited Competition for the Continuation of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial (U01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-06-502
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.849
CFDA Descriptions:	Kidney Diseases, Urology and Hematology Research
Current Application Deadline:	No deadline provided
Original Application Deadline:	Jul 26, 2006
Posted Date:	May 31, 2006
Creation Date:	May 31, 2006
Archive Date:	Aug 25, 2006
Total Program Funding:	$19,500,000
Maximum Federal Grant Award:	$3,900,000
Minimum Federal Grant Award:
Expected Number of Awards:	1
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Foreign institutions are not eligible to apply. -You may submit a grant application if your organization received a Notice of Grant Award (U01 DK61700) for the FAVORIT Trial. -The objective of the continuation of the FAVORIT Trial is to complete recruitment and to continue intervention and follow-up of the enrolled study participants. Therefore, the single applicant for this RFA should be the organizations which served as the Operations Center, the Data Coordinating Center, the Central Laboratory, and the Endpoint Adjudication Center during the previous project period.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Investigations on Primary Immunodeficiency Diseases (R01); • Grants for Basic Research in Glomerular Diseases (R01); • Advances in Polycystic Kidney Disease (R01); • Ancillary Studies of Kidney Disease Accessing Information from Clinical Trials, Epidemiolo...; • Calcium Oxalate Stone Diseases (R01); • Research Grants for Clinical Studies of Kidney Diseases; • Chronic Prostatitis Collaborative Research Network (Cpcrn); • Frequent Hemodialysis Clinical Trials
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...